OHSU
Return to Listing

13 result(s) for Prostate

PI Name Protocol # Title
Julie Graff IRB00005254 A Phase II Study of CTLA Blockade by Ipilimumab plus Androgen Suppression Therapy in Patients with an Incomplete Response to AST Alone for Metastatic Prostate Cancer
Tomasz Beer IRB00005688 A Phase II study of MAOA inhibitor plus docetaxel in patients currently receiving and progressing on docetaxel therapy
Julie Graff IRB00008787 A Phase 2 Study of Increased-Dose Abiraterone Acetate in Patients with Castration Resistant Prostate Cancer (CRPC)
Joshi Alumkal IRB00008791 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer
Tomasz Beer IRB00009204 Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Adaptive Mechanisms of Resistance
Joshi Alumkal IRB00009259 Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men with Castration-Resistant Prostate Cancer
Julie Graff IRB00009352 A phase 2, randomized, 3-arm study of abiraterone acetate alone, abiraterone acetate plus degarelix, a GnRH antagonist, and degarelix alone for patients with prostate cancer with a rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy
Julie Graff IRB00009363 PVAMC / OHSU J: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Tomasz Beer IRB00009497 LCCC 1231: Observational Longitudinal Study of Pain in Men with Metastatic Castrate-Resistant Prostate Cancer
Joshi Alumkal IRB00010241 Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment
Xin Li IRB00010345 Contrast Enhanced MRI of the Prostate
Sara Walker IRB00010379 Prospective Investigation of the Quality of Life, Emotional Functioning, and Treatment Satisfaction among Patients in Radiation Medicine
Julie Graff IRB00010586 A three arm randomized, open-label Phase II study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg, and versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080
 

You may qualify for additional trials within our Phase 1 Program